Ilex Medical Ltd (TLV:ILX)
Israel · Delayed Price · Currency is ILS · Price in ILA 4,850.00
-285.00 (-5.55%)
Oct 7, 2026, 5:24 PM IDT
Ilex Medical Ratios and Metrics
Market cap in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 546 | 746 | 842 | 663 | 1,081 | 1,834 | |
Market Cap Growth | -23.57% | -11.47% | 27.01% | -38.64% | -41.07% | 32.20% |
Enterprise Value | 377 | 550 | 716 | 555 | 926 | 1,705 |
Last Close Price | 48.81 | 64.44 | 70.75 | 54.58 | 86.89 | 142.18 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.03 | 13.43 | 21.61 | 13.04 | 10.58 | 9.29 |
PS Ratio | 0.62 | 0.80 | 0.92 | 0.72 | 1.25 | 1.73 |
PB Ratio | 0.81 | 1.09 | 1.30 | 1.06 | 1.76 | 3.19 |
P/TBV Ratio | 0.84 | 1.12 | 1.35 | 1.11 | 1.86 | 3.34 |
P/FCF Ratio | 11.21 | 16.25 | 16.24 | 20.95 | 24.79 | 7.98 |
P/OCF Ratio | 6.36 | 10.24 | 10.32 | 8.25 | 15.50 | 6.78 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.43 | 0.59 | 0.78 | 0.61 | 1.07 | 1.61 |
EV/EBITDA Ratio | 4.94 | 6.17 | 7.41 | 4.44 | 4.72 | 5.75 |
EV/EBIT Ratio | 12.86 | 9.86 | 11.40 | 7.17 | 6.33 | 6.93 |
EV/FCF Ratio | 7.74 | 11.99 | 13.80 | 17.52 | 21.25 | 7.42 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.10 |
Debt / EBITDA Ratio | 0.55 | 0.45 | 0.47 | 0.39 | 0.26 | 0.20 |
Debt / FCF Ratio | 1.01 | 1.01 | 0.99 | 1.52 | 1.18 | 0.26 |
Net Debt / Equity Ratio | -0.25 | -0.28 | -0.29 | -0.27 | -0.28 | -0.39 |
Net Debt / EBITDA Ratio | -2.24 | -2.11 | -1.92 | -1.35 | -0.89 | -0.76 |
Net Debt / FCF Ratio | -3.48 | -4.11 | -3.58 | -5.33 | -3.99 | -0.98 |
Asset Turnover | 0.93 | 0.94 | 0.92 | 0.96 | 0.97 | 1.28 |
Inventory Turnover | 4.06 | 4.08 | 4.43 | 4.51 | 4.43 | 5.39 |
Quick Ratio | 2.11 | 1.99 | 1.88 | 1.86 | 2.11 | 2.12 |
Current Ratio | 3.07 | 2.83 | 2.68 | 2.46 | 2.81 | 2.63 |
Return on Equity (ROE) | 5.85% | 8.35% | 7.20% | 8.98% | 18.25% | 38.76% |
Return on Assets (ROA) | 2.81% | 3.51% | 3.90% | 5.05% | 10.31% | 18.60% |
Return on Invested Capital (ROIC) | 6.22% | 8.74% | 10.17% | 12.98% | 28.15% | 55.66% |
Return on Capital Employed (ROCE) | 5.70% | 7.60% | 8.60% | 10.50% | 21.70% | 38.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.12% | 7.45% | 4.63% | 7.67% | 9.45% | 10.77% |
FCF Yield | 8.92% | 6.15% | 6.16% | 4.77% | 4.03% | 12.53% |
Dividend Yield | 4.09% | 3.08% | 1.72% | 2.50% | 2.21% | 3.74% |
Payout Ratio | 57.12% | 24.56% | 39.16% | 42.14% | 58.75% | 30.38% |
Buyback Yield / Dilution | -0.18% | - | 0.02% | 0.79% | 0.02% | -5.73% |
Total Shareholder Return | 3.91% | 3.08% | 1.74% | 3.29% | 2.22% | -1.98% |